ProShare Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

ProShare Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,656	Closed	-$51K	–	2179
2022 Q1	$51K	Sell	10,656 -2,518	-19%	-$7.59K	﹤0.01%	2115
2021 Q4	$49K	Buy	+13,174	New	+$70.3K	﹤0.01%	2289
2015 Q1	–	Sell	-51	Closed	-$27K	–	1947
2014 Q4	$27K	Sell	51 -43	-46%	-$19.4K	﹤0.01%	1949
2014 Q3	$140K	Sell	94 -21	-18%	-$30.4K	﹤0.01%	2096
2014 Q2	$157K	Sell	115 -41	-26%	-$47.6K	﹤0.01%	2259
2014 Q1	$217K	Buy	+156	New	+$181K	﹤0.01%	2470
2013 Q4	–	Sell	-97	Closed	-$101K	–	1918
2013 Q3	$101K	Buy	97 +5	+5%	+$5.34K	﹤0.01%	2416
2013 Q2	$100K	Buy	+92	New	+$103K	﹤0.01%	2255

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

ProShare Advisors's VIRX Position: Q2 2022 in Review

ProShare Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2022, closing a stake of 10,656 shares — an estimated $51K sold.

ProShare Advisors first reported a position in VIRX in Q2 2013 and held it in 8 quarters. The position peaked at $217K in Q1 2014. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2022.

ProShare Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
ProShare Advisors sold 10,656 Viracta Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $51K.
ProShare Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 8 quarters.
ProShare Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $217K in Q1 2014.
63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.